MAIA Biotechnology 2025 Highlights: Ateganosine Clinical Progress and Funding Support
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Source: NASDAQ.COM
- Clinical Trial Progress: As of May 15, 2025, Ateganosine demonstrated a median overall survival of 17.8 months in the THIO-101 trial for NSCLC, indicating its potential efficacy in heavily pre-treated patients and offering a new treatment option.
- FDA Fast Track Designation: In July 2025, Ateganosine received FDA Fast Track designation, recognizing its potential as a treatment for NSCLC, which is expected to expedite its market entry process.
- Funding Support: In September 2025, MAIA secured a $2.3 million grant from the NIH to expand the Phase 2 trial of THIO-101, while raising $17.6 million in capital throughout 2025, enhancing its research capabilities and financial stability.
- Strategic Collaboration Agreement: In June 2025, MAIA entered into a master agreement with Roche to conduct combination trials of Ateganosine with other drugs, further expanding its application potential in multiple hard-to-treat cancers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MAIA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MAIA
Wall Street analysts forecast MAIA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MAIA is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.390
Low
14.00
Averages
14.00
High
14.00
Current: 2.390
Low
14.00
Averages
14.00
High
14.00
No data
About MAIA
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oncolytics Biotech Strengthens Leadership to Advance Clinical Programs
- Leadership Enhancement: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to advance the company's registration-directed programs in gastrointestinal cancers.
- Breakthrough Efficacy Data: The company reported that pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite stable metastatic colorectal cancer patients when combined with standard chemotherapy, significantly surpassing the historical 6-11% response rate, indicating its potential in difficult-to-treat patient populations.
- FDA Designation Approval: Oncolytics secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the initiation of the only immunotherapy registration trial planned for this challenging area, further solidifying its market position.
- Advisory Board Expansion: The company has expanded its Scientific Advisory Board by adding globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, laying the groundwork for accelerated clinical development across multiple indications.
Continue Reading
MAIA Biotechnology 2025 Highlights: Ateganosine Clinical Progress and Funding Support
- Clinical Trial Progress: As of May 15, 2025, Ateganosine demonstrated a median overall survival of 17.8 months in the THIO-101 trial for NSCLC, indicating its potential efficacy in heavily pre-treated patients and offering a new treatment option.
- FDA Fast Track Designation: In July 2025, Ateganosine received FDA Fast Track designation, recognizing its potential as a treatment for NSCLC, which is expected to expedite its market entry process.
- Funding Support: In September 2025, MAIA secured a $2.3 million grant from the NIH to expand the Phase 2 trial of THIO-101, while raising $17.6 million in capital throughout 2025, enhancing its research capabilities and financial stability.
- Strategic Collaboration Agreement: In June 2025, MAIA entered into a master agreement with Roche to conduct combination trials of Ateganosine with other drugs, further expanding its application potential in multiple hard-to-treat cancers.
Continue Reading